title: Oralair®: sublingual immunotherapy for the treatment of grass pollen allergic rhinoconjunctivitis.
abstract: Oralair(®) is a sublingual grass pollen immunotherapy tablet that was authorized for use in Europe on 26 November 2009 and is currently in Phase III clinical trials in the USA. It is indicated for the management of grass pollen allergic rhinitis with or without conjunctivitis in adults, adolescents and children (above the age of 5) with clinically relevant symptoms, confirmed by a positive cutaneous test and/or a positive titer of the specific IgE to the grass pollen. Treatment is composed of an initiation phase (3-day dose escalation: 100 IR [index of reactivity] on day 1, 200 IR on day 2 and 300 IR on day 3) and a continuation phase at a dosage of 300 IR/day. Treatment is scheduled to start approximately 4 months before the actual start of the pollen season and should be continued throughout the season. The treatment should be prescribed and initiated by an experienced allergy specialist.
authors.affiliation: UMDNJ New Jersey Medical School, 90 Bergen Street, Newark, NJ 07103, USA. jison.hong@gmail.com
authors.forename: Jison
authors.initials: J
authors.lastname: Hong
authors.forename: Leonard
authors.initials: L
authors.lastname: Bielory
mesh_terms: D000286:Administration, Sublingual; D000485:Allergens / Q000009:adverse effects / Q000276:immunology; D002985:Clinical Protocols; D017326:Clinical Trials, Phase III as Topic; D003231:Conjunctivitis; D003888:Desensitization, Immunologic; D005060:Europe; D006109:Poaceae / Q000276:immunology; D011058:Pollen / Q000009:adverse effects; D012220:Rhinitis; D006255:Rhinitis, Allergic, Seasonal / Q000188:drug therapy* / Q000276:immunology / Q000503:physiopathology; D014481:United States
chemical_list: D000485:Allergens